© Copyright 2025 American Medical Association. All rights reserved.
The hepatitis B vaccine (HepB) is designed to provide active, long-term immunity against hepatitis B, a serious liver infection that can lead to chronic disease, hospitalization, and even death. Unlike immune globulins, which offer short-term, passive immunity, vaccines stimulate the recipient's immune system to produce its own antibodies. This process involves exposing the immune system to altered versions of the hepatitis B virus, prompting it to recognize and remember how to combat the virus in future encounters. The HepB vaccine is particularly significant as it not only protects against the immediate effects of the virus but also mitigates the risk of long-term complications, such as hepatocellular carcinoma, making it one of the pioneering cancer vaccines in medical use. The vaccine can be derived from the blood plasma of asymptomatic carriers or synthesized through recombinant technology, where a plasmid containing the hepatitis gene is inserted into baker's yeast. This yeast is then lysed, and the components are purified to create the vaccine. The CPT® Code 90759 specifically refers to the adult 3-antigen hepatitis B vaccine, which includes the S, Pre-S1, and Pre-S2 surface antigens, administered in a three-dose schedule via intramuscular injection. It is important to note that this code solely reports the vaccine product, and the administration of the injection should be billed separately.
© Copyright 2025 Coding Ahead. All rights reserved.
The hepatitis B vaccine (HepB) is indicated for individuals who require protection against hepatitis B virus infection. The following conditions and circumstances warrant the administration of this vaccine:
The administration of the hepatitis B vaccine involves several key procedural steps to ensure proper delivery and effectiveness:
Following the administration of the hepatitis B vaccine, patients are typically advised to remain in the healthcare setting for a short period to monitor for any immediate allergic reactions. Common post-injection reactions may include soreness at the injection site, mild fever, or fatigue, which usually resolve within a few days. Patients should be informed about the importance of completing the full three-dose schedule to ensure optimal immunity. Follow-up appointments should be scheduled to administer the subsequent doses, typically at 0, 1, and 6 months after the initial dose. It is also essential to educate patients on the signs of potential adverse reactions and when to seek medical attention.
Short Descr | HEP B VAC 3AG 10MCG 3 DOS IM | Medium Descr | HEP B VACC 3 AG 10 MCG 3 DOSE SCHED FOR IM USE | Long Descr | Hepatitis B vaccine (HepB), 3-antigen (S, Pre-S1, Pre-S2), 10 mcg dosage, 3 dose schedule, for intramuscular use | Related Drugs | PREHEVBRIO | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | APC Status Indicator | Influenza, Pneumococcal Pneumonia, Hepatitis B, and Covid-19 Vaccines; Monoclonal Antibody Therapy Product | ASC Payment Indicator | Corneal tissue acquisition, hepatitis B vaccine; paid at reasonable cost. | Type of Service (TOS) | 1 - Medical Care | Berenson-Eggers TOS (BETOS) | none | MUE | 1 |
59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | GC | This service has been performed in part by a resident under the direction of a teaching physician |
Date
|
Action
|
Notes
|
---|---|---|
2023-01-01 | Added | First appearance in CodeBook. |
2022-07-01 | Note | FDA approval granted. |
2022-01-01 | Added | Code added. Effective upon receiving emergency Use Authorization or approval from the FDA. |